Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Clinical trial NCT02196857 · COMPLETED
Trial details
- NCT number
- NCT02196857
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-06
- Primary completion
- 2018-11-27
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.